Advertisement

Applied Health Economics and Health Policy

, Volume 6, Issue 1, pp 41–53 | Cite as

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia

A 12- and 24-month follow-up from the e-STAR database in Spain
  • José M. OlivaresEmail author
  • Alfonso Rodriguez-Martinez
  • José A. Burón
  • David Alonso-Escolano
  • Alexander Rodriguez-Morales
Original Research Article

Abstract

Background

The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment and lead to improved clinical and economic outcomes for patients with schizophrenia.

Objectives

To investigate the cost effectiveness of treatment with long-acting injectable risperidone compared with previous antipsychotic regimens in patients with schizophrenia enrolled in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain.

Methods

e-STAR is an international, long-term, ongoing, observational study of schizophrenia patients who, during their routine course of clinical practice, are started on a new antipsychotic treatment.

In e-STAR, data are collected at baseline, retrospectively over a minimum period of 12 months and up to a maximum of 24 months, and prospectively at 3-month intervals for 24 months after the start of a new antipsychotic drug. For the purpose of this study, patients who started treatment with long-acting injectable risperidone during their routine clinical management and were enrolled in the e-STAR study in Spain were eligible. The effectiveness of long-acting injectable risperidone compared with previous antipsychotic treatment, defined as the absence of hospitalizations or relapses, was assessed at 12 and 24 months of treatment. Acquisition costs of antipsychotic drug therapy were based on the official registered price. Drug prices from source were in €, year 2005 values; hospital costs from source were in €, year 2001 values, and were inflated to reflect 2005 costs. Complete follow-up data were available for 788 patients at 12 months after starting long-acting injectable risperidone and for 757 patients at 24 months.

Results

In terms of effectiveness, at 12 months after switching to long-acting injectable risperidone, there was a higher percentage of patients who did not require hospitalization (89.1%), did not relapse (85.4%) or neither required hospitalization nor relapsed (82.4%) as compared retrospectively with the same period for the previous treatment (67%, 47.8% and 59.8%, respectively). The corresponding figures at 24 months also favoured treatment with long-acting injectable risperidone (85.2% vs 60%, 88.5% vs 47.4% and 77% vs 53.6%, respectively). Treatment with long-acting injectable risperidone was associated with higher medication costs per month compared with previous antipsychotic medication after 12 (€405.80 vs €128.16) and 24 months (€407.33 vs €142.77) of follow-up. Cost effectiveness per month per patient was lower for risperidone than previous antipsychotic medication in the three patient scenarios: without hospitalization (€539.82 vs €982.13), without relapse (€519.67 vs €1242.03) and without hospitalization and without relapse (€597.22 vs €1059.39).

Conclusions

Treatment with long-acting injectable risperidone compared with previous antipsychotic medications resulted in a higher number of patients not requiring hospitalization, not relapsing, and not requiring hospitalization and not showing relapse, resulting in risperidone being more cost effective per month per patient.

It is important to note that real-world variations in adherence would automatically be controlled from within a randomized control trial, and hence, any evaluation of variations in adherence inevitably requires a real-world focus. On the basis of these findings, which were obtained in real-world clinical practice, long-acting injectable risperidone is predicted to be the dominant strategy because it results in effective symptom control and direct medical cost savings. However, because of limitations in methodology, any conclusions should, at this stage, be treated as tentative, and confirmation in more detailed follow-up studies is required. Cost-effectiveness comparisons based on experimental evaluations of relapse minimization strategies are also required. In order to avoid estimation biases in the future, a prospectively designed study is needed.

Keywords

Schizophrenia Risperidone Antipsychotic Medication Antipsychotic Treatment Psychotic Episode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors gratefully acknowledge the unrestricted sponsorship funding provided by Janssen-Cilag. José M. Olivares is member of national and international advisory boards for Janssen-Cilag, Lilly and Astra Zeneca, has been involved in designing and participating in clinical trials for Janssen-Cilag, Lilly, Astra Zeneca, Lundbeck and Bristol-Myers, and has received educational grants for research, honoraria and travel support for activities as a consultant/advisor and lecturer/faculty member for Janssen-Cilag, Lilly, Astra Zeneca, Lundbeck, Bristol-Myers and Glaxo-Smith-Klein.

Alfonso Rodriguez-Martinez has received honoraria as a consultant/advisor for Janssen-Cilag, Pfizer, Astra Zeneca, Aventis and Bristol-Myers.

Jose A. Burón is the Medical Director of the Medical Department of Janssen-Cilag and owns stock in Johnson & Johnson.

David Alonso-Escolano is the Medical Affairs Manager of Psychiatry of the Medical Department of Janssen-Cilag and owns stock in Johnson & Johnson.

Alexander Rodriguez-Morales is the Group Medical Affairs Manager of Psychiatry for the Medical Department of Janssen-Cilag and owns stock in Johnson & Johnson.

We thank Marta Pulido, MD, for editing the manuscript and for editorial assistance.

e-STAR Spanish Study Group: J.C. Villalobos Vega, J. Alonso Cuéllar, F.J. Alberca de Castro, C. Morillo-Velarde Quintero, J. F. Román Martíin, P. Tabares Domínguez, J.L. Prados Ojeda, S. Sanz Cortés, F.I. Mata Cala, C. Gutiérrez Marín, L. Moyano Castro, M.A. Haza Duaso, J. Requena Albarracín, G. Narbona Vergara, J.A. Fernández Benítez, F. Mayoral Cleries, J.M. García-Herrera Pérez-Brian, A. Bordallo Aragón, J.C. Rodríguez Navarro, J.A. Algarra Biedma, R. Bravo de Pedro, J.F. Delgado González, M.E. Jaén López, H. Díaz Moreno, J.A. Soto López, E. Ojeda Rodríguez, C. Martínez de Hoyos, M. Pardilla Sacristán, M.D. Molina Martín, E. Martín Ballesteros, P.A. Sopelana Rodríguez, L. Fernández Menéndez, R. Santos Rivas, P. del Pino Cuadrado, J. Correas Lauffer, J.J. Rodríguez Solano, J.M. Fernández Martínez, F. García Solano, P. García-Lamberde Rodríguez, J.A. Romero Rodríguez, T. Rodríguez Cano, M. Ducaju Fortacin, J.M. Blanco Lobeiras, J.M. Piñeiro Sampedro, A. Pérez Bravo, A. Fernández Pellicer, M.D. Alonso López, J. Fraga Liste, M. Riobo Fernández, A. Casas Losada, R. Vazquez-Noguerol Mendez, S. Agra Romero, J.J. Blanco Blanco, I. Tortajada Bonaselt, M.C. García Mahia, E. Ferrer Gómez del Valle, P. Quiroga Yañez, M. Gelabert Camarasa, J.A. Barbado Alonso, G. Florez Mendez, F. Doce Feliz, M.A. López Lamela, M. Vega Piñero, P. Fuentes Alvarado, I. López Gómez, P. Fadon Martín, J.L. Santos Gómez, A. García López, R. Rodríguez Jiménez, A. Escudero Nafs, N. Casas Barquero, R. Fernández-Villamor Ortiz, J.L. Velez Noguera, P. Ruiz Carrasco, J. Martín Muñoz, M. Masegoza Palma, C. Marín Hortelano, L. Sánchez Bonome, J. Sánchez Sevilla, J.M. Mongil San Juan, J.M. García Ramos, J.L. Vallejo Muñoz, J. Elorza Guisasola, L. Santamaria Vazquez, F. Campo Guerras, F.J. Arrufat Nebot, F.J. Baron Fernández, A.L. Palomo Nicolau, R. Catala Subirats, M. Messays Kidias, V. Fabregat Navarro, B. Frades García, F. Mejias del Rosal, T. de Vicente Muñoz, J. Año Ballester, P. Malabia Lieb, A. Delgado Martel, E. Roca Bea, I. Grau Joaquim, F. Boatas Enjuanes, M. Bañuelos Piñol, E. Fontova i Carbonell, R. Martín Muñoz, C. Argila Giribets, L. Albages Sans, A. Serrano Blanco, M. Arcega Felipe, P. González Muñoz, A. Pons Villanueva, M. Bernardo Arroyo, R. Coronas Borri, S. Miret Fallada, M. Celma Merola, E. Parellada Rodon, J.R. Pigem Palmes, E. Pérez Martínez, J. Matarredona Catala, A. Sandoval Coca, F. Pascual Ferrandiz, E. Ferrandiz Paya, G. Iturri Caballero, A. Franco Bonet, J. Fluvia Figueras, P. Moreno Pagador, M. Medina Garibo, V. Pérez Camo, C. Sanz Carrillo, C. Pelegrin Valero, F.J. Caro Rebollo, J. García Campayo, J.M. Sala Ayma, M. Martínez Roig, M.A. de Uña Mateos, R. García Bertolin, A. Martín García, F. Jiménez Mazo, J.L. Galvez Velasco, L. Santa Maria Pérez, C. Jiménez Casado, J.J. Mancheño Barba, M. Conde Diaz, J.P. Alcon Rubio, A. Soler Mandoli, A. Uson Herrero, A. Rodríguez Martínez, P. Salgado Serrano, E. Nieto Rodríguez, J. Segui Montesinos, J. Ferragud Macia, A. Mateos Marcos, J.V. Pérez-Fuster Soto, M. Verdaguer Dumont, J. Parra Pagan, V. Balanza Martínez, M. Santiuste de Pablos, C. Espinosa Delgado, M.D. Martínez Quiles, F.J. Manzanera López, P. Pozo Navarro, A. Micol Torres, F.J. Martínez Ingles, J.M. Salmeron Arias-Camison, J.C. López Manzano, R. Villanueva Peña, G. Petersen Guitarte, H. Blasco Fontecilla, J. Barjau Romero, R. Sanz Gil, J. Marín Lozano, L. Donaire Adanez, I. Zarranz Herrera-Oria, J. Pérez Jiménez, F. Carrato Vaz, O. Sanz García, C. Contreras Anton, R. Reixach Casula, M.C. Natividad Hernandez, F. Teba Escabias, J. Rodríguez Torresano, A. Huidobro Pérez-Villamil, L. Estevez, M. Aragües Figuero, A. Muñoz de Morales, J.L. Rodríguez Calvin, M. Delgado Criado, V. Molina Rodríguez, E. Balbo Ambrosolio, P.M. Holgado Madera, G. Ponce Alfaro, M.M. Rojas Vidal, A. García Valtuille, O. Ruiz, G. Lucas Cabornero, M. Echevarria Martínez de Bujo, M.J. Maicas Mallen, J. Santandreu Puigros, A. Liñana Martorell, A. Clar Forteza, E. Rodríguez Arrebola, M. Rodríguez de la Torre, C.G. Anton Saiz, C. Bardolet i Casas, E. Rodríguez Linde, R. De Arce Cordon, E.M. Padial Molina, F.J. Ruiz Carazo, J.J. Muro Romero, D. Vico Cano, M. Soria Dorado, S. Campos Velazquez, A.J. Rodríguez Sánchez, S. Ocio Leon, H. Pachas Sánchez, M. Henry Benitez, A. Intxausti Zugarramurai, M.A. Contreras, M. De la Varga González, P. Barreiro Marín, F. Gómez Robina, M. Sánchez García, F.J. Otero Pérez, P. Cubero Bros, A. Carrillo Gómez, J. de Dios Molina Martín, J.L. Carrasco Perera, M. C. Averbach, J.L. Carrasco Perera, E. Goenaga Palancares, M.T. Gallego de Dios, C. Fernández Rojo, S. Sánchez Iglesias, M.I. Rubio Merino, N. Prieto Mestre, A. Pérez Urdaniz, J.M. Martínez Sánchez, R. Gordo Seco, J. Franco Muñoz, M. Mateos Agut, M.L. Blanco Lozano, F. Martín Herguedas, A. Torcal Pena, J. Vicente García, A. Varona Martínez, O. Sanz Granado, M.A. Medina Fernández, J.M. Moran Canseco, P.A. Megia López, M.A. Franco Martín, J.A. Espina Barrio, J. Giner Ubago, M. Roca Bennassar, J.M. Olivares Díez, J.L. Hernandez Fleta, F. Porras Fortes, C. Arango López, O. Medina, D. Figuera Alvarez, J.M. Peña Roca, G. Rubio Valladolid, J.A. Furquet Tavera, J.A. García-Castrillon Sales, I. Batalla Llordes, C. Anchuistegui Melgarejo, F. Cañas de la Paz, V. Vallés Callol, M. Bousoño García, J. Bobes García, F.J. Vaz Leal, E. Cáceres Corrales, E. Sánchez Iglesias, M.A. Carreiras Gómez, G. García Serrano, E.G. Román Chillarón, F.J. Samino Aguado, J J. Molina Castillo, A. González González, J. Gallardo Vázquez, M. Bolivar Peralvarez, M. Rios Diaz, M. Ybarzabal Mesa, F.J. Acosta Artiles, M. Ajoy Chao, M. Ybarzabal Mesa, P. del Rosario Santana, M.A. García Escudero, M. Molla Berenguer, J.M. Bonete Llacer, J.A. Juan Berna, J. Barragán Ortiz, L. Tost Pardell, C. Hernández-Alvarez de Sotomayor, M.R. Cejas Méndez, R. Cabrera Garate, B. Díaz Múgica, M. Caballero González, J. Pujol Domingo, C. Sáez Navarro, G. Selva Vera, M.A. Cuquerella, J. Lonjedo Monzo, P. Cervera Boada, M.F. Martín Pérez, E. Carrasco Parrado, J.J. Yañez Sánchez and J. Calvo Fernández.

References

  1. 1.
    McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13PubMedCrossRefGoogle Scholar
  2. 2.
    Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Pham Physician 2007; 75: 1821–9Google Scholar
  3. 3.
    Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006; 32 Suppl. 1: S44–63CrossRefGoogle Scholar
  4. 4.
    Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46: 871–81PubMedCrossRefGoogle Scholar
  5. 5.
    Bromet EJ, Naz B, Fochtmann LJ, et al. Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia. Schizophr Bull 2005; 31: 639–49PubMedCrossRefGoogle Scholar
  6. 6.
    Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48: 978–86PubMedCrossRefGoogle Scholar
  7. 7.
    Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738–49PubMedCrossRefGoogle Scholar
  8. 8.
    American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(4 Suppl.): 1–63Google Scholar
  9. 9.
    National Collaborating Centre for Mental Health and the National Institute for Clinical Excellence. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and the Royal College of Psychiatrists & the British Psychological Society, 2003 [online]. Available from URL: http://www.nice.org.uk/Guidance/CG1 [Accessed 2008 Feb 18]Google Scholar
  10. 10.
    Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1–10PubMedCrossRefGoogle Scholar
  11. 11.
    Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209–22PubMedCrossRefGoogle Scholar
  12. 12.
    Wang X, Savage R, Borisov A, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res 2006; 40: 669–76PubMedCrossRefGoogle Scholar
  13. 13.
    Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRefGoogle Scholar
  14. 14.
    Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007; 10: 23–41PubMedGoogle Scholar
  15. 15.
    Oliva-Moreno J. The costs of schizophrenia in Spain. Eur J Health Econ 2006; 7: 182–8PubMedCrossRefGoogle Scholar
  16. 16.
    Lang HC, Su TP. The cost of schizophrenia treatment in Taiwan. Psychiatr Serv 2004; 55: 928–30PubMedCrossRefGoogle Scholar
  17. 17.
    Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66: 1122–9PubMedCrossRefGoogle Scholar
  18. 18.
    Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835–42PubMedCrossRefGoogle Scholar
  19. 19.
    Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509–16PubMedCrossRefGoogle Scholar
  20. 20.
    Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–51PubMedCrossRefGoogle Scholar
  21. 21.
    Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005; 21: 2017–28PubMedCrossRefGoogle Scholar
  22. 22.
    Rémillard S, Pourcher E, Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. J Int Neuropsychol Soc 2008; 14: 110–8PubMedCrossRefGoogle Scholar
  23. 23.
    Gaebel W, Riesbeck M, Wolwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763–74PubMedCrossRefGoogle Scholar
  24. 24.
    Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250–7PubMedCrossRefGoogle Scholar
  25. 25.
    Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–32PubMedCrossRefGoogle Scholar
  26. 26.
    Martin SD, Libretto SE, Pratt DJ, et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003; 19: 298–305PubMedCrossRefGoogle Scholar
  27. 27.
    Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084–9PubMedCrossRefGoogle Scholar
  28. 28.
    Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007; 40: 257–63PubMedCrossRefGoogle Scholar
  29. 29.
    Niaz OS, Haddal PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007; 116: 36–46PubMedCrossRefGoogle Scholar
  30. 30.
    Baca E, Bobes J, Canas F, et al. Cost-effectiveness analysis of long-acting injectable risperidone v. olanzapine and v. fluphenazine decanoate in treating schizophrenia [in Spanish]. Rev ESp Econ Salud 2005; 4: 273–85Google Scholar
  31. 31.
    Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics 2005; 23 Suppl. 1: 3–16Google Scholar
  32. 32.
    Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 Suppl. 1: 17–33PubMedGoogle Scholar
  33. 33.
    Laux G, Heeg B, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005; 23 Suppl. 1: 49–61Google Scholar
  34. 34.
    Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62–74Google Scholar
  35. 35.
    De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005; 23 Suppl. 1: 35–47Google Scholar
  36. 36.
    Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23 Suppl. 1: 75–89Google Scholar
  37. 37.
    Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Pharmacoeconomics 2005; 23 Suppl. 1: 1–2Google Scholar
  38. 38.
    Sinaem prescribing information [online]. Available from URL: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm [Accessed 2008 Feb 18]
  39. 39.
    Medicom SA. Vademecum internacional. Madrid: Medi Medic, 2005Google Scholar
  40. 40.
    Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. Aliment Pharmacol Ther 2006; 23: 409–19CrossRefGoogle Scholar
  41. 41.
    Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin. 2006 Feb; 22(2): 241–55PubMedCrossRefGoogle Scholar
  42. 42.
    Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007; 13: 453–60PubMedCrossRefGoogle Scholar
  43. 43.
    Lorca PM, Miadi-Fargier H, Lançon C, et al. Cost-effectiveness analysis of schizophrenia patient care settings: impact of an atypical antipsychotic under long-acting injection [in French]. Encephale 2005; 31: 235–46CrossRefGoogle Scholar
  44. 44.
    Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • José M. Olivares
    • 1
    • 4
    Email author
  • Alfonso Rodriguez-Martinez
    • 2
  • José A. Burón
    • 3
  • David Alonso-Escolano
    • 3
  • Alexander Rodriguez-Morales
    • 3
  1. 1.Department of Psychiatry, Hospital MeixoeiroComplejo Hospitalario Universitario de VigoVigoSpain
  2. 2.Centro Forum Hospital del MarBarcelonaSpain
  3. 3.Medical DepartmentJanssen-CilagMadridSpain
  4. 4.Servicio de Psiquiatria, Hospital MeixoeiroComplejo Hospitalario Universitario de VigoVigoEspaña

Personalised recommendations